Cipher Pharmaceuticals (PHE) Stock Statistics & Valuation Metrics
Total Valuation
Cipher Pharmaceuticals has a market cap or net worth of EUR 211.80M. The enterprise value is EUR 420.80M.
- Market Cap
- EUR 211.80M
- Enterprise Value
- EUR 420.80M
Share Statistics
Cipher Pharmaceuticals has 25,415,071 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 25,415,071
- Owned by Insiders
- 41.67%
- Owned by Institutions
- 3.68%
Financial Efficiency
Cipher Pharmaceuticals’s return on equity (ROE) is 0.22 and return on invested capital (ROIC) is 12.78%.
- Return on Equity (ROE)
- 0.22
- Return on Assets (ROA)
- 0.18
- Return on Invested Capital (ROIC)
- 12.78%
- Return on Capital Employed (ROCE)
- 0.13
- Revenue Per Employee
- 10.27M
- Profits Per Employee
- 5.56M
- Employee Count
- 5
- Asset Turnover
- 0.33
- Inventory Turnover
- 2.15
Valuation Ratios
The current PE Ratio of Cipher Pharmaceuticals is 8.21. Cipher Pharmaceuticals’s PEG ratio is 0.06.
- PE Ratio
- 8.21
- PS Ratio
- 4.83
- PB Ratio
- 1.74
- Price to FCF
- 8.84
- Price to Operating Cash Flow
- 8.79
- PEG Ratio
- 0.06
Income Statement
In the last 12 months, Cipher Pharmaceuticals had revenue of 51.33M and earned 27.81M in profits. Earnings per share was 1.09.
- Revenue
- 51.33M
- Gross Profit
- 33.77M
- Operating Income
- 16.80M
- Pretax Income
- 17.46M
- Net Income
- 27.81M
- EBITDA
- 24.10M
- Earnings Per Share (EPS)
- 1.09
Cash Flow
In the last 12 months, operating cash flow was 27.05M and capital expenditures -122,937, giving a free cash flow of 26.93M billion.
- Operating Cash Flow
- 27.05M
- Free Cash Flow
- 26.93M
- Free Cash Flow per Share
- 1.06
Dividends & Yields
Cipher Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 11.35%
- Earnings Yield
- 12.22%
Stock Price Statistics
- Beta
- 0.12
- 52-Week Price Change
- -7.43%
- 50-Day Moving Average
- 8.47
- 200-Day Moving Average
- 9.58
- Relative Strength Index (RSI)
- 45.82
- Average Volume (3m)
- 500
Important Dates
Cipher Pharmaceuticals upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 11, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Cipher Pharmaceuticals as a current ratio of 1.12, with Debt / Equity ratio of 4.36%
- Current Ratio
- 1.12
- Quick Ratio
- 0.79
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- -0.08
- Interest Coverage Ratio
- 14.17
Taxes
In the past 12 months, Cipher Pharmaceuticals has paid -10.34M in taxes.
- Income Tax
- -10.34M
- Effective Tax Rate
- -0.59
Enterprise Valuation
Cipher Pharmaceuticals EV to EBITDA ratio is 9.35, with an EV/FCF ratio of 8.49.
- EV to Sales
- 4.64
- EV to EBITDA
- 9.35
- EV to Free Cash Flow
- 8.49
- EV to Operating Cash Flow
- 8.45
Balance Sheet
Cipher Pharmaceuticals has EUR 9.10M in cash and marketable securities with EUR 366.40K in debt, giving a net cash position of EUR 8.73M billion.
- Cash & Marketable Securities
- EUR 9.10M
- Total Debt
- EUR 366.40K
- Net Cash
- EUR 8.73M
- Net Cash Per Share
- EUR 0.34
- Tangible Book Value Per Share
- EUR 1.98
Margins
Gross margin is 70.55%, with operating margin of 38.75%, and net profit margin of 58.81%.
- Gross Margin
- 70.55%
- Operating Margin
- 38.75%
- Pretax Margin
- 35.22%
- Net Profit Margin
- 58.81%
- EBITDA Margin
- 49.59%
- EBIT Margin
- 38.75%
Analyst Forecast
The average price target for Cipher Pharmaceuticals is EUR 12.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 12.75
- Price Target Upside
- 57.41% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- -2.75%
- EPS Growth Forecast
- 127.87%
Scores
- Smart Score
- 6
- AI Score
- ―